Jeff is the Managing Partner of Maytal Capital, a healthcare-focused private equity and venture capital firm he founded in 2017, an Operating Partner at Revival Healthcare Capital, a medical device-focused private equity firm, and a Partner at Bridge Builders Collaborative, an early-stage venture firm focused on mindfulness and mental health. He previously served as the global CEO for Sandoz and Alcon at Novartis Group (NYSE: NVS).
Jeff serves on the board of directors of Amneal Pharmaceuticals (NYSE: AMRX), a leader in specialty and generic pharmaceuticals with $2 billion in revenues; Dorian Therapeutics, a cell therapy biotech spun out of Stanford University; 908 Devices (NASDAQ: MASS), a pioneer in life science diagnostics, and Wishbone Medical, a leader in pediatric orthopedic medical devices. He also serves on several non-profit boards including Education Opens Doors, where he is Chairman, the North Texas Food Bank and YPO of Dallas.
Between 2008 and 2016, Jeff served on the Executive Committee of Switzerland-based Novartis Group, first as the global CEO of Germany-based Sandoz, Novartis’s generic pharma and biosimilar subsidiary, and then as CEO of Texas-based Alcon, Novartis’s $10 billion revenue eye care division, which was spun out from Novartis in 2019 as a publicly listed firm (NYSE: ALC). At both Sandoz and Alcon, Jeff was responsible for leading over 25,000 associates across more than 160 countries and had leadership responsibility for all functions, regions, and franchises.
Prior to this, Jeff headed Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharmaceuticals, leading a team of over 3,000 people across 65 markets and serving on its Executive Committee, and as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Before joining Novartis, Jeff was a Senior Director of Strategic Planning & Business Development at Gap Inc. and an Engagement Manager with McKinsey & Co., both in San Francisco.
Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was a John W. Watzek Fellow. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College. Jeff currently serves as a Board Trustee at his Minneapolis high school alma mater, Breck School.
Jeff previously served on the Board of Directors of AdvaMed, the medical device industry association and at Roam Analytics, a Silicon Valley-based artificial intelligence healthcare software firm sold to Parexel in 2020. He was twice named to Fortune’s “40 under 40” list of up-and-coming leaders globally and has lived in seven countries on four continents. He is married and lives with his wife and two daughters in Dallas and enjoys running, skiing, live music, yoga, meditation, travel and foreign affairs.